Research Article
Patterns of Progression in Metastatic Estrogen Receptor Positive Breast Cancer: An Argument for Local Therapy
Table 1
Treatment characteristics by course of endocrine therapy.
| | | Entire cohort | Diffuse progression | Limited progression (<3 sites) | | Entire cohort | Oligoprogression | Oligometastatic + progression |
| | Courses, | 195 | 150 | 45 | 28 | 18 |
| | Type of therapy by course, (%) | | | | | | | Aromatase inhibitor | 77 (39%) | 58 (39%) | 19 (42%) | 13 (48%) | 6 (33%) | | AI + GNRH agonist | 29 (15%) | 23 (15%) | 6 (13%) | 2 (7%) | 4 (22%) | | AI + everolimus | 13 (7%) | 11 (7%) | 2 (4%) | 2 (7%) | 0 (0%) | | AI + fulvestrant | 14 (7%) | 9 (6%) | 5 (11%) | 4 (15%) | 1 (6%) | | Fulvestrant | 38 (19%) | 30 (20% | 8 (18%) | 3 (11%) | 5 (28%) | | Tamoxifen | 22 (11%) | 17 (11%) | 5 (11%) | 3 (11%) | 2 (1%) | | Other | 2 (1%) | 2 (1%) | 0 (0%) | 0 (0%) | 0 (0%) |
| | Additional treatments, (%) | | | | | | | Bisphosphonate use | 102 (52%) | 77 (51%) | 25 (56%) | 19 (70%) | 6 (33%) | | Her2 target therapy | 37 (19%) | 19 (13%) | 16 (36%) | 7 (26%) | 9 (50%) |
| Mean time to progression
(per course) | 8 (1–61) months | 8 (1–38) months | 9 (2–61) months | 12 (2–30) months | 6 (2–61) months |
|
|
AI: aromatase inhibitor; GNRH: gonadotropin-releasing hormone.
|
